Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr;11(2):96-100.
doi: 10.1159/000444357. Epub 2016 Apr 26.

Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer

Barbara Ingold Heppner  1 , Sibylle Loibl  2 , Carsten Denkert  3
Affiliations
Review

Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer

Barbara Ingold Heppner et al. Breast Care (Basel). 2016 Apr.

Abstract

There is clear evidence that the immune system plays an essential role in tumor defense. By determining tumor-infiltrating lymphocytes (TILs), the individual immunological response becomes more apparent and measurable. In breast cancer, high levels of TILs are associated with a more favorable clinical course. In this review, we describe how TILs are determined with emphasis on daily routine diagnostics. We further discuss their impact as a prognostic and predictive biomarker in the neoadjuvant and adjuvant therapy setting as well as in residual disease. We also discuss their potential future implications on further stratifying prognostic subgroups of breast cancer, thereby possibly influencing future therapy considerations.

Keywords: Adjuvant; Breast cancer; Neoadjuvant; Pathological complete response; Tumor-infiltrating lymphocytes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Lymphocyte predominant breast cancer (LPBC). b The infiltrate is predominantly located in the tumor stroma.
See this image and copyright information in PMC

References

    1. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836–848. - PubMed
    1. Geissler EK. Post-transplantation malignancies: Here today, gone tomorrow? Nat Rev Clinical Oncol. 2015;12:705–717. - PubMed
    1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–360. - PubMed
    1. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73. - PubMed
    1. Ghiringhelli F, Apetoh L. The interplay between the immune system and chemotherapy: Emerging methods for optimizing therapy. Expert Rev Clin Immunol. 2014;10:19–30. - PubMed